Interferon alfa
Top View
- Direct Effects of Type I Interferons on Cells of the Immune System
- Withdrawal of the Marketing Authorisation Application for Joulferon (Albinterferon Alfa-2B)
- Neulasta and Pegfilgrastim Biosimilars 1931-A SGM P2020 © 2020 CVS Caremark
- Pegylation Πa Well-Proven Strategy for the Improvement of Recombinant
- White Blood Cell Colony Stimulating Factors
- Biologic & Other Novel Agents
- Granulocyte-Colony Stimulating Factor for Antiviral-Associated Neutropenia: Systematic Review and Economic Evaluation [Technology Report Number 115]
- Induction Pegylated Interferon Alfa-2A and High Dose Ribavirin Do Not Increase SVR in Heavy Patients with HCV Genotype 1 and High Viral Loads
- Current Status of Granulocyte–Macrophage Colony-Stimulating
- Interferon Gamma-1B) / ALFERON® N (Interferon Alfa-N3) / INFERGEN® (Interferon Alfacon-A) / INTRON® a (Interferon Alfa-2B)
- Hypersensitivity Reactions to Biological Drugs M Corominas,1 G Gastaminza,2 T Lobera3
- Neulasta Fulphila Udenyca Ziextenzo Nyvepria
- Interferon Alfa-2B | Memorial Sloan Kettering Cancer Center
- Pegylation of Therapeutic Proteins Simona Jevsevar, Menci Kunstelj, Vladka Gaberc Porekar
- Interferon Alfa-2B
- INTRON a Therapy
- (INN) for Biological and Biotechnological Substances
- Supplemental Material BMJ Support Palliat Care Doi: 10.1136/Bmjspcare